Hal Barron, GlaxoSmithKline R&D chief (GSK via YouTube)
April 14, 2021 05:11 PM EDTUpdated April 15, 06:51 AM
R&D

Glax­o­SmithK­line scraps two key mid-stage tri­als for their ICOS drug in the lat­est set­back for the field

John Carroll

Editor & Founder

An­oth­er ICOS can­cer drug pro­gram is run­ning in­to stormy weath­er, with more bad news for Glax­o­SmithK­line R&D chief Hal Bar­ron.

GSK put out word on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Kally­ope qui­et­ly re­ports Phase 2 obe­si­ty da­ta, be­gins mid-stage mi­graine tri­al

Start­up work­ing on oral an­ti­bod­ies shares ear­ly ul­cer­a­tive col­i­tis da­ta

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times